Metsera, Inc. is a biopharmaceutical company focused on developing peptide-based medicines for obesity and other metabolic and cardiometabolic diseases. The company aims to address unmet needs in weight management and related metabolic conditions through hormone-inspired therapeutics.
Metsera’s pipeline spans discovery through development and is built on peptide engineering, optimization, and formulation capabilities. Its R&D centers on creating long-acting, selective therapeutics intended to improve efficacy and tolerability in metabolic disease treatment.